Description
TEVIMBRA (tislelizumab-jsgr) is an intravenous injection used as an immunotherapy drug that blocks programmed death receptor-1 (PD-1) to help the immune system fight certain cancers. Manufactured by BeOne Medicines USA, Inc., it's available as a 10 mg/mL solution concentrate, approved under BLA761232 and marketed since March 2024. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name |
Format |
Description |
Link |
|
21 |
Access the FDA dataset for Tislelizumab-jsgr — ANDA 761232 submitted by Mylan Institutional LLC
|
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232 |
Tags
- drug-safety
- drug-information
- drug-manufacturers
- public-health
- prescription-drugs